Valuation : Marker Therapeutics, Inc.

Market Cap 21.68M 18.71M 17.62M 16.08M 30.01M 2.06B 30.24M 209M 80.91M 1.05B 81.39M 79.61M 3.44B P/E 2026 *
-2.19x
P/E 2027 * -1.48x
Enterprise Value 21.68M 18.71M 17.62M 16.08M 30.01M 2.06B 30.24M 209M 80.91M 1.05B 81.39M 79.61M 3.44B EV / Sales 2026 *
5.11x
EV / Sales 2027 * 1.07x
Free-Float
94.51%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Marker Therapeutics, Inc.

1 day-3.85%
1 week-17.76%
Current month-6.02%
1 month+10.62%
3 months-17.76%
6 months-15.54%
Current year-16.11%
1 week 1.24
Extreme 1.24
1.5
1 month 1.08
Extreme 1.085
1.6
Current year 1.05
Extreme 1.05
2.46
1 year 0.83
Extreme 0.83
2.46
3 years 0.81
Extreme 0.8099
6.8
5 years 0.67
Extreme 0.6706
20.5
10 years 0.67
Extreme 0.6706
135.5
Manager TitleAgeSince
Chief Executive Officer 46 2023-04-30
Chief Operating Officer 36 2023-11-30
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 46 2018-10-16
Chairman 65 2022-05-23
Director/Board Member 62 2019-08-05
Date Insider Type Main position Quantity % Market Cap. Importance
11/17/25 Free

Chairman

221,741 1.7138%
11/17/25 Free

Director

221,741 1.7138%
11/17/25 Free

Director

221,741 1.7138%
Change 5-day change 1-year change 3-year change Capi.($)
-3.85%-17.76%+35.03%-77.02% 21.68M
+0.97%-1.75%+2.17%+18.46% 49.74B
-0.30%-1.02%+451.04%+496.95% 44.98B
+2.13%+1.70%+38.27%+17.61% 42.52B
+0.87%-3.88%+18.21%+73.17% 40.78B
-0.90%-1.74%+15.20%+48.44% 32.89B
+2.71%+5.66% - - 17.09B
+1.68%-3.43%+24.71%+116.83% 16.28B
+1.70%-1.75%+12.00%+28.50% 14.4B
+3.34%-1.98%+78.65%+39.19% 13.48B
Average +0.84%-3.63%+75.03%+84.68% 27.22B
Weighted average by Cap. +1.01%-2.25%+97.62%+123.24%

Financials

2026 *2027 *
Net sales 4.24M 3.66M 3.45M 3.15M 5.87M 403M 5.92M 40.82M 15.83M 205M 15.93M 15.58M 673M 20.19M 17.42M 16.41M 14.97M 27.95M 1.92B 28.16M 194M 75.35M 975M 75.8M 74.14M 3.2B
Net income -11.84M -10.22M -9.62M -8.78M -16.39M -1.12B -16.51M -114M -44.18M -572M -44.44M -43.47M -1.88B -18.09M -15.61M -14.71M -13.42M -25.05M -1.72B -25.24M -174M -67.53M -874M -67.93M -66.45M -2.87B
Net Debt - -
Logo Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company’s multi antigen recognizing (MAR)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. It is developing two product candidates, including an Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601) and an Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601 to recognize multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
Employees
5
Date Price Change Volume
26-09-02 US$1.250 -3.85% 167,576
26-09-01 US$1.300 -2.26% 21,028
26-08-31 US$1.330 -2.92% 59,539
26-08-28 US$1.370 -6.16% 84,785
26-08-27 US$1.460 +0.69% 24,507
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.300USD
Average target price
7.867USD
Spread / Average Target
+505.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRKR Stock